USA flag logo/image

An Official Website of the United States Government

Hip Joint Resurfacing with Functional Human Cartilage

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85361
Program Year/Program:
2007 / STTR
Agency Tracking Number:
AR055414
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CYTEX THERAPEUTICS INC.
2608 ERWIN ROAD DURHAM, NC 27715-1317
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Hip Joint Resurfacing with Functional Human Cartilage
Agency: HHS
Contract: 1R41AR055414-01
Award Amount: $236,632.00
 

Abstract:

DESCRIPTION (provided by applicant): Degenerative joint disease accounts for substantial human suffering at tremendous social and economic cost. While prosthetic joint replacement is a well-established procedure, a finite life span makes this treatment una cceptable for younger or active individuals who often require progressively complicated revision surgeries. The goal of this Phase I STTR is to develop an implant suitable for complete resurfacing of an osteoarthritic femoral head of the human hip joint an d proven ability to integrate with bone by using stem cells and a cartilage-mimetic scaffold. The two novelties of this work are: (i) accelerated generation of mechanically functional cartilage within a brief period of in vitro culture and (ii) resurfacing of an entire joint instead of a focal defect. We will create a hemispherical layer of cartilage that replicates the load-bearing properties of the native tissue by combining adult human stem cells with a biomaterial scaffold made by a new three-dimensiona l (3D) weaving technology and a novel, highly scalable cell culture device. Maturation and growth of the engineered tissue will be monitored by non-destructive MRI and biomechanical testing, and functional integration with vital bone will be assessed using a subcutaneous pouch model in an immunodeficient rodent. The combination of these emergent regenerative medical technologies is expected to provide a novel means of developing functional tissue engineered constructs that can improve the success of cartila ge repair procedures. This project represents a Phase I STTR to combine adult human stem cell and three-dimensional weaving technologies to create a layer of cartilage that can integrate with bone. The two primary novelties of this work are: (i) accele rated generation of mechanically functional cartilage within a brief period of in vitro culture and (ii) resurfacing of an entire joint instead of a focal defect. The ultimate goal of this study is to develop a tissue engineering approach that can be used to resurface large segments of the joint that have been affected by degenerative diseases such as osteoarthritis.

Principal Investigator:

Lisa E. Freed
6172530460
LFREED@MIT.EDU

Business Contact:

Geoffrey R. Erickson
cytex.therapeutics@gmail.com
Small Business Information at Submission:

CYTEX THERAPEUTICS INC.
CYTEX THERAPEUTICS INC. BOX 2685 DURHAM, NC 27715

EIN/Tax ID: 120524389
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
MASSACHUSETTS INSTITUTE OF TEC
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
77 MASSACHUSETTS AVE
CAMBRIDGE, MA 2139
RI Type: Nonprofit college or university